Milestones from 20 years

Experienced into the future

Ever since the company was founded, the name Vita 34 has been standing for innovation and quality. Vita 34 owns a wide range of products and is able to ensure the suitability of the stem cell deposits for therapeutic applications by means of high-quality and reliable preparation and long-term storage at the highest safety standards.

Vita 34 is the only private stem cell bank in Germany to report a multitude of medical applications of the stem cell deposits stored for private medical precaution. Besides the practice of applications, Vita 34 stands out due to a multitude of intensive research activities. Vita 34 participates actively in the applied stem cell research in order to examine the optional medical applications of stem cells from cord blood and to develop new products based on stem cells.

We have been not only storing umbilical cord blood for 20 years, but have set standards through our experience, research, and innovations – for the future.

 

2017

  • The European Patent Office grants Vita 34 the patent for the cryo-preservation of umbilical cord tissue
  • 150000th storage of cord blood preparation at Vita 34
  • Vita 34 celebrates the 20th company anniversary

 

2016

  • 145000th storage of cord blood preparation at Vita 34
  • Vita 34 wins innovation award Top 100 as one of the most innovative companies in Germany
  • Introduction of new donation product “VitaMine&Yours”
  • Vita 34 concludes cooperation agreements on storages from Dubai and Lebanon and on the set-up of a stem cell bank in China according to German standards
  • Dr. Wolfgang Knirsch becomes Chief Marketing Officer (CMO)

 

CEO of Vita 34, Dr. Andre Gerth, accepts “Top 100” award

 

2015

  • Storage of 135000th cord blood deposit at Vita 34
  • 29th and 30th application of Vita 34 cord blood preparations
  • Vita 34 takes over Danish cord blood bank StemCare
  • Vita 34 concludes cooperation agreements on storages from Lithuania, Estonia, and Latvia
  • Falk Neukirch becomes the new Chief Financial Officer (CFO)

 

2014

  • 100000th storage of cord blood deposit at Vita 34
  • 28th application of Vita 34 cord blood preparation
  • Introduction of Vita 34 app “Our baby”

 

2013

  • Storage of 90000th cord blood preparation at Vita 34
  • 25th application of Vita 34 cord blood preparation
  • Vita 34 receives permit to store umbilical cord tissue

 

2012 

  • 20th application of Vita 34 cord blood preparation
  • First mobile stem cell team for transplantations established
  • Vita 34 concludes new distribution partnership with BioSave (Serbia)
  • Merger with BioPlanta GmbH, Dr. André Gerth becomes Chief Executive Officer (CEO) of Vita 34 AG

 

Mobile stem cell team of Vita 34

 

2011

  • Storage of 80000th cord blood preparation at Vita 34
  • Start of research project on the production of biological anti-freeze proteins
  • Introduction of new, freely accessible register for stem cells from the umbilical cord: www.stemcellsearch.org
  • First transplantation of a VitaPlusDonation preparation

 

2010

  • Storage of 70000th cord blood preparation at Vita 34
  • Promotion of Vita 34 research activities at the amount of 769,000 Euro by the Free State of Saxony and the European Regional Development Fund
  • Takeover of majority of Secuvita S.L. (Spain)

 

70000th storage of cord blood deposit at Vita 34

 

2009

  • Start of study on the application of autologous umbilical cord blood in diabetes type 1 together with the diabetes research group from the Technical University of Munich
  • Vita 34 concludes new distribution partnerships with Izvorna Celica (Slovenia) and Sorgente (Italy)

 

2008

  • Storage of 50000th cord blood preparation at Vita 3
  • Promotion of Vita 34 research work at the amount of 2 million Euro by the Free State of Saxony
  • First transplantation of a Vita 34 preparation in a Spanish boy with cerebral pals

 

2007

  • Vita 34 International is listed at the Frankfurt Stock Exchange
  • Introduction of “VitaPlusDonation” product – combination of stem cell storage and optional donation

 

Vita 34 is listed at the Frankfurt Stock Exchange

 

2006

  • License for the allogeneic release of umbilical cord blood granted by Paul Ehrlich Institute (facility of the Federal Ministry of Health)
  • Vita 34 concludes new distribution partnership with Secuvita (Spain)

 

2005

  • First application of Vita 34 cord blood preparation in Germany
  • Publication of important research results on the therapy of heart attacks
  • Introduction of proprietary, improved collection kit
  • StemCare Denmark becomes franchisee

 

2004

  • Promotion of Vita 34 research work at the amount of 410,000 Euro by the Free State of Saxony
  • First autologous cord blood transplantation of Vita 34 preparation in a child with acute lymphatic leukemia in the U

 

2003

  • Removal to the BioCity Leipzig and opening of worldwide first “glass stem cell laboratory” at the BioCity Leipzig
  • Presentation of important research results on the therapy of stroke

 

Vita 34 moves to the BioCity Leipzig

 

2002

  • Promotion of Vita 34 research work at the amount of 720,000 Euro by the Free State of Saxony
  • Change of corporate form: Vita 34 GmbH becomes a public limited company
  • Introduction of “Vita 34 Sibling Initiative”

 

1997

  • Vita 34 GmbH in Leipzig is founded by Dr. med. Eberhard Lampeter and fellow physicians
  • First company in Europe providing for the private storage of umbilical cord blood